ID

19753

Description

Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00389285

Link

https://clinicaltrials.gov/show/NCT00389285

Keywords

Versions (1)
  1. 1/26/17 1/26/17 -
Uploaded on

January 26, 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Carcinoma, Renal Cell NCT00389285

English

Eligibility Carcinoma, Renal Cell NCT00389285

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of rcc of predominantly clear cell histology
Description

Conventional (Clear Cell) Renal Cell Carcinoma

Data type

boolean

Alias
UMLS CUI [1]
C0279702
either no prior treatment or a maximum of 2 prior treatment regimens for metastatic rcc that included no more than 1 treatment regimen targeting the vascular endothelial growth factor (vegf) pathway (phase 1 only)
Description

Therapeutic procedure Quantity Metastatic Renal Cell Cancer | Therapeutic procedure Targeting VEGF Signaling Pathway

Data type

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0278678
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C1521840
UMLS CUI [2,3]
C2984329
at least 1 but no more than 2 prior systemic therapies for metastatic rcc that included no more than 1 therapy targeting the vegf pathway (phase 2 only)
Description

systemic therapy Quantity Metastatic Renal Cell Cancer | Therapeutic procedure Targeting VEGF Signaling Pathway

Data type

boolean

Alias
UMLS CUI [1,1]
C1515119
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0278678
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C1521840
UMLS CUI [2,3]
C2984329
disease measurable per the response evaluation criteria in solid tumors (recist) (phase 2 only)
Description

Measurable Disease

Data type

boolean

Alias
UMLS CUI [1]
C1513041
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
presence of acute infection or other significant systemic illness
Description

Communicable Disease | Systemic disease Significant

Data type

boolean

Alias
UMLS CUI [1]
C0009450
UMLS CUI [2,1]
C0442893
UMLS CUI [2,2]
C0750502
central nervous system involvement by malignancy
Description

Central Nervous System Involvement

Data type

boolean

Alias
UMLS CUI [1]
C4050309
history of other cancer within 5 years
Description

Malignant Neoplasms

Data type

boolean

Alias
UMLS CUI [1]
C0006826
previously received ril-21 or sorafenib
Description

rIL-21 | sorafenib

Data type

boolean

Alias
UMLS CUI [1]
C1831593
UMLS CUI [2]
C1516119
Back to the top of the page

Similar models

Eligibility Carcinoma, Renal Cell NCT00389285

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Conventional (Clear Cell) Renal Cell Carcinoma
Item
diagnosis of rcc of predominantly clear cell histology
boolean
C0279702 (UMLS CUI [1])
Therapeutic procedure Quantity Metastatic Renal Cell Cancer | Therapeutic procedure Targeting VEGF Signaling Pathway
Item
either no prior treatment or a maximum of 2 prior treatment regimens for metastatic rcc that included no more than 1 treatment regimen targeting the vascular endothelial growth factor (vegf) pathway (phase 1 only)
boolean
C0087111 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0278678 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1521840 (UMLS CUI [2,2])
C2984329 (UMLS CUI [2,3])
systemic therapy Quantity Metastatic Renal Cell Cancer | Therapeutic procedure Targeting VEGF Signaling Pathway
Item
at least 1 but no more than 2 prior systemic therapies for metastatic rcc that included no more than 1 therapy targeting the vegf pathway (phase 2 only)
boolean
C1515119 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0278678 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1521840 (UMLS CUI [2,2])
C2984329 (UMLS CUI [2,3])
Measurable Disease
Item
disease measurable per the response evaluation criteria in solid tumors (recist) (phase 2 only)
boolean
C1513041 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Communicable Disease | Systemic disease Significant
Item
presence of acute infection or other significant systemic illness
boolean
C0009450 (UMLS CUI [1])
C0442893 (UMLS CUI [2,1])
C0750502 (UMLS CUI [2,2])
Central Nervous System Involvement
Item
central nervous system involvement by malignancy
boolean
C4050309 (UMLS CUI [1])
Malignant Neoplasms
Item
history of other cancer within 5 years
boolean
C0006826 (UMLS CUI [1])
rIL-21 | sorafenib
Item
previously received ril-21 or sorafenib
boolean
C1831593 (UMLS CUI [1])
C1516119 (UMLS CUI [2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial